Jason Imbriglio

Jason Imbriglio has a diverse work experience in the field of discovery chemistry and pharmacology. Jason is currently a member of the Scientific Advisory Board at PhoreMost Ltd since June 2023. Prior to that, they held the position of VP Head of Discovery Chemistry, Applied Modeling, and Pharmacology at Covant Therapeutics since September 2022. Jason also briefly worked as the Head of Discovery Chemistry and Pharmacology at Roivant Newco in September 2022. Before transitioning to these roles, they had an extensive career at Merck, where they held various positions including Director of Chemical Biology, Principal Scientist, Research Fellow, and Senior Research Chemist. At Merck, they worked from May 2004 to January 2021. Prior to joining Merck, their experience includes roles at Roivant Sciences as VP - Head of Discovery Chemistry and Roivant Discovery, and VP - Head of Platform Technology from January 2021 to September 2022.

Jason Imbriglio's education history begins from 1992 to 1997, when they attended the University of Massachusetts Amherst. During this time, they pursued a Bachelor of Arts (B.A.) in Biology and a Bachelor of Science (BS) in Chemistry.

Following their undergraduate studies, Imbriglio pursued a higher level of education and enrolled at the University of Arizona from 1997 to 2002. It was during this time that they achieved a Doctor of Philosophy (Ph.D.) in Organic Chemistry.

Finally, Imbriglio attended Boston College from 2002 to 2004. However, no specific degree or field of study is mentioned for this period.